Pipeline Watchlist
Company Pipelines
Companies
4assets
- agenT-797agenT-797 / Allogeneic native iNKT cell therapy / Oncology and ImmunologyCritical pulmonary immune failure (severe hypoxemic respiratory failure/pneumonia/ARDS)Phase 2randomized adaptive placebo-controlled ongoingUSSolid tumor cancers (checkpoint-refractory, incl. gastric/esophageal/GEJ adenocarcinoma)Phase 2investigator-sponsored ongoing (NCT06251973)USGraft-versus-host disease (GvHD prevention)expanding development
- MiNK-215MiNK-215 / FAP / IL-15 armored FAP-CAR-iNKT cell therapy / OncologySolid tumors (NSCLC, CRC liver metastases)PreclinicalIND-enabling studies underway
- MiNK-413MiNK-413 / BCMA / IL-15 armored BCMA-CAR-iNKT cell therapy / OncologyMultiple myelomaPreclinical
- PRAME TCR-iNKTPRAME / TCR-engineered iNKT cell therapy / OncologyPediatric cancers/solid tumorsPreclinicalIND-enabling
4assets
- bitopertinGlyT1 / Small Molecule / HematologyErythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)Phase 3OngoingGlobalDiamond-Blackfan AnemiaPhase 2OngoingUS
- DISC-0974DISC-0974 / Hemojuvelin (HJV) / Monoclonal Antibody / HematologyAnemia of Myelofibrosis (MF)Phase 2OngoingGlobalAnemia of Chronic Kidney Disease (CKD)Phase 1/Phase 2OngoingGlobalAnemia of Inflammatory Bowel Disease (IBD)Phase 2PlannedGlobal
- DISC-3405DISC-3405 / TMPRSS6 (Matriptase-2) / Monoclonal Antibody / HematologyPolycythemia Vera (PV)Phase 2OngoingGlobalSickle Cell Disease (SCD)Phase 1bOngoingGlobal
- DISC-0998DISC-0998 / Hemojuvelin (HJV) / Monoclonal Antibody / HematologyInflammatory-disease-associated anemiaPreclinicalOngoingGlobal
4assets
- SelinexorKPT-330 / XPOVIO / XPO1 (Exportin 1) / Small Molecule / OncologyMultiple MyelomaMarketedActiveUSGlobalEndometrial CancerPhase 3ActiveUSGlobalMyelofibrosisPhase 3ActiveUSGlobal
- EltanexorKPT-8602 / XPO1 (Exportin 1) / Small Molecule / OncologyMyelodysplastic NeoplasmsPhase 2PausedUSColorectal CancerPhase 2PausedUSProstate CancerPhase 2PausedUS
- KPT-9274KPT-9274 / PAK4 / NAMPT / Small Molecule / OncologySolid Tumors & LymphomaPhase 1PausedUS
- VerdinexorKPT-335 / XPO1 (Exportin 1) / Small Molecule / Veterinary Oncology / Infectious DiseasesCanine LymphomaMarketedActiveUS
4assets
- IFx-2.0IFx-Hu2.0 / Innate Immune System / Personalized Cancer Vaccine / Innate Immune Agonist / OncologyAdvanced or Metastatic Merkel Cell Carcinoma (1st line, adjunctive to pembrolizumab)Phase 3OngoingUnited StatesMerkel Cell Carcinoma of Unknown Primary (MCCUP)Phase 1/Phase 2OngoingUnited States
- TBS-2025KVA12123 / VISTA / Monoclonal Antibody / OncologyAdvanced Solid Tumor CancerPhase 1OngoingUnited StatesmutNPM1 Acute Myeloid Leukemia (AML)Phase 1/Phase 2PlannedUnited States
- Bi-functional ADCsMyeloid-derived suppressor cells (MDSCs) / Antibody-Drug Conjugate (ADC) / OncologySolid TumorsPreclinicalOngoingUnited States
- REM-001Unknown / Photodynamic Therapy / OncologyCutaneous Metastatic Breast Cancer (CMBC)Phase 3OngoingUnited States
4assets
- PAS-004PAS-004 / MEK 1/2 / Macrocyclic Small Molecule / Oncology / Rare DiseasesNeurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN)MAPK pathway-driven advanced solid tumors
- PAS-003PAS-003 / α5β1 Integrin / Monoclonal Antibody / NeurologyAmyotrophic Lateral Sclerosis (ALS)
- PAS-001PAS-001 / C4A / Small Molecule / PsychiatrySchizophrenia
- PAS-002PAS-002 / NeurologyMultiple Sclerosis (MS)
4assets
- ZiftomenibKO-539 / KOMZIFTI / Menin-KMT2A/MLL interaction / Small molecule / Hematologic MalignanciesR/R NPM1-mutated AMLNewly Diagnosed AMLFLT3-mutated AML
- DarlifarnibKO-2806 / Farnesyl transferase / Small molecule / OncologyClear cell renal cell carcinoma (ccRCC)Solid tumors
- TipifarnibFarnesyl transferase / Small molecule / OncologyHRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC)PIK3CA-dependent HNSCC
- KO-7246KO-7246 / Menin / Small molecule / CardiometabolicDiabetesCardiometabolic disease
4assets
4assets
4assets
- SAT-3247SAT-3247 / AAK1 / Small molecule / Degenerative muscle diseasesDuchenne Muscular Dystrophy (DMD)Facioscapulohumeral Muscular Dystrophy (FSHD)
- SAT-3153SAT-3153 / Notch polarity kinase / Small molecule / Degenerative muscle diseasesDuchenne Muscular Dystrophy (DMD)
- BertilimumabiCo-008 / Eotaxin-1 (CCL11) / Monoclonal antibody / ImmunologyBullous Pemphigoid
- iCo-019iCo-019 / Fungal cell membrane / Small molecule (Oral Amphotericin B) / Infectious DiseasesFungal infections
4assets
- GivastomigCLDN18.2 x 4-1BB / Bispecific Antibody / OncologyGastric CancerGastrointestinal Malignancies
- RagistomigPD-L1 x 4-1BB / Bispecific Antibody / OncologySolid Tumors
- UliledlimabCD73 / Monoclonal Antibody / OncologyCancer
- VIS-101VEGF-A x ANG-2 / Bispecific Antibody / OphthalmologyWet Age-Related Macular Degeneration (AMD)Diabetic Macular Edema (DME)
4assets
- NEO100NEO-100 / Unknown / Small Molecule / Oncology, NeurologyMalignant GliomasGrade 4 AstrocytomaParkinson's Disease
- NEO212NEO-212 / DNA / Small Molecule Conjugate / OncologyMalignant Gliomas
- NEO214NEO-214 / DR5, PDE4 / Small Molecule Conjugate / OncologyGlioblastoma (GBM)Multiple Myeloma
- NEO400NEO-400 / Unknown / Small Molecule Conjugate / Dermatology, OncologyUV-Induced Skin DamageTopical Oncology
4assets
- TaletrectinibIBTROZI / ROS1 / Small Molecule / OncologyAdvanced ROS1+ NSCLC
- SafusidenibmIDH1 / Small Molecule / OncologyDiffuse IDH1-mutant gliomaAstrocytomaOligodendroglioma
- NUV-1511NUV-1511 / Undisclosed / Drug-Drug Conjugate (DDC) / OncologyAdvanced solid tumors
- NUV-868NUV-868 / BET (BD2-selective) / Small Molecule / OncologyAdvanced solid tumors
4assets
- NarsoplimabOMS721 / Yartemlea / MASP-2 / Monoclonal antibody / Hematology / Complement-Mediated DiseasesHematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
- ZaltenibartOMS906 / MASP-3 / Monoclonal antibody / Hematology / NephrologyParoxysmal nocturnal hemoglobinuria (PNH)C3 glomerulopathy
- OMS1029OMS1029 / MASP-2 / Biologic / Complement-Mediated Diseases
- OMS527OMS527 / PDE7 / Small molecule / AddictionCocaine use disorder
4assets
- leniolisibJoenja
- napazimoneKL1333
- conestat alfaRUCONEST
4assets
- UlixacaltamidePRAX-944 / T-type calcium channel / Small molecule / NeurologyEssential Tremor
- RelutriginePRAX-562 / Persistent sodium current (NaV) / Small molecule / NeurologyDevelopmental and Epileptic Encephalopathies (DEEs)SCN2A-DEESCN8A-DEE
- VormatriginePRAX-628 / Sodium channels (NaV) / Small molecule / NeurologyFocal Onset EpilepsyEpilepsy
- ElsunersenSCN2A mRNA / Antisense oligonucleotide (ASO) / NeurologySCN2A Developmental and Epileptic Encephalopathy
4assets
4assets
- ABBV-RGX-314surabgene lomparvovec / sura-vec
- RGX-121clemidsogene lanparvovec / NAVSUNLI
4assets
- ZovegalisibRLY-2608 / Mutant PI3Kα / Small molecule / Oncology & Genetic DiseaseHR+/HER2- metastatic breast cancer (PI3Kα-mutated)Phase 3ActiveGlobalPIK3CA-driven vascular malformations/anomaliesPhase 1ActiveGlobal
- LirafugratinibRLY-4008 / FGFR2 / Small molecule / OncologyFGFR2-altered solid tumorsClinicalOut-licensedGlobal
- RLY-8161RLY-8161 / NRAS / Small molecule / OncologyNRAS-driven solid tumorsPreclinicalActiveGlobal
- Fabry disease programUndisclosed / Non-inhibitory chaperone / Genetic DiseaseFabry diseasePreclinicalActiveGlobal
4assets
- IMCIVREEsetmelanotide
- bivamelagonLB54640
- Preclinical small moleculesCongenital hyperinsulinism (CHI)
4assets
- SCY-770PXL-770 / AMP-activated protein kinase (AMPK) / Small Molecule / Rare Diseases / NephrologyAutosomal Dominant Polycystic Kidney Disease (ADPKD)Phase 2ActiveGlobal
- SCY-247SCY-247 / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment and Prevention of Invasive Fungal InfectionsPhase 1ActiveUnited States
- Fungerp analogs1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesTreatment of resistant fungiPreclinicalActiveGlobal
- IbrexafungerpSCY-078 / BREXAFEMME / 1,3-beta-glucan synthase / Small Molecule / Infectious DiseasesVulvovaginal candidiasis (VVC) and Recurrent VVCApprovedActiveUnited StatesInvasive Candidiasis (IC)Phase 3ActiveGlobal
4assets
- SEP-479SEP-479 / PTH1R / Small Molecule / EndocrinologyHypoparathyroidismPhase 1Active
- SEP-631SEP-631 / MRGPRX2 / Small Molecule / Immunology and InflammationChronic spontaneous urticaria (CSU)Phase 1ActiveOther mast cell diseasesPhase 1Active
- TSHR ProgramTSHR / Small Molecule / EndocrinologyGraves' diseasePreclinicalActiveThyroid eye diseasePreclinicalActive
- Novo Nordisk Partnered ProgramsGLP-1R, GIPR, GCGR, Undisclosed / Small Molecule / Metabolic DiseasesMetabolic diseasesDiscoveryActive
4assets
- SPC-15SPC-15 / 5-HT4 receptor agonist / Small Molecule / PsychiatryPTSD and stress-induced anxiety disordersPreclinicalActiveGlobal
- SP-26SP-26 / NMDA receptor antagonist / Implant / NeurologyFibromyalgia and chronic painPreclinicalActiveGlobal
- SPC-14SPC-14 / Unknown / Small Molecule / NeurologyAlzheimer's diseasePreclinicalActiveGlobal
- SPU-16SPU-16 / Unknown / Peptide / NeurologyMultiple sclerosisPreclinicalActiveGlobal
4assets
- patidegibSGT-610 / Hedgehog signaling pathway (SMO) / Small molecule / DermatologyGorlin syndrome (prevention of new BCC lesions)High-frequency basal cell carcinoma (BCC)
- erlotinibSGT-210 / EGFR / Small molecule / DermatologyUndisclosed indications
- tretinoin and benzoyl peroxide cream, 0.1%/3%TWYNEO / Retinoid receptors / Bacterial proteins / Small molecule / DermatologyAcne vulgaris
- benzoyl peroxide cream, 5%EPSOLAY / Bacterial proteins / Small molecule / DermatologyInflammatory lesions of rosacea
4assets
4assets
- TSC-100TSC-100 / HA-1 / TCR-T Cell Therapy / Hematologic MalignanciesAcute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States
- TSC-101TSC-101 / HA-2 / TCR-T Cell Therapy / Hematologic MalignanciesAcute Myeloid Leukemia (AML) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesAcute Lymphoblastic Leukemia (ALL) (Post-HCT Relapse Prevention)Phase 1ActiveUnited StatesMyelodysplastic Syndromes (MDS) (Post-HCT Relapse Prevention)Phase 1ActiveUnited States
- ImmunoBank TCR-T CandidatesT-Plex / Multiple Targets (e.g., PRAME, HPV16, MAGE-A1) / Multiplexed TCR-T Cell Therapy / OncologySolid TumorsPhase 1ActiveUnited States
- Novel TargetsUnidentified Autoantigens / Targeted Therapeutics / Autoimmune DisordersCrohn's DiseaseDiscoveryActiveUnited States
4assets
4assets
- VXA-CoV2-3.3VXA-CoV2-3.3 / SARS-CoV-2 / Oral recombinant adenovirus vaccine / Infectious DiseasesCOVID-19
- Norovirus Oral Vaccine CandidateNorovirus (GI.1 and GII.4) / Oral recombinant adenovirus vaccine / Infectious DiseasesNorovirus InfectionAcute Gastroenteritis
- Seasonal Influenza Oral Vaccine CandidateVXA-A1 / Influenza Virus / Oral recombinant adenovirus vaccine / Infectious DiseasesSeasonal Influenza
- HPV Therapeutic Vaccine CandidateHuman Papillomavirus (HPV) / Oral recombinant therapeutic vaccine / OncologyHPV-associated Cancers / Immuno-oncology
4assets
- AzetukalnerXEN1101 / Kv7.2/Kv7.3 potassium channel opener / Small Molecule / Neurology and PsychiatryFocal Onset Seizures (FOS)Phase 3OngoingGlobalPrimary Generalized Tonic-Clonic Seizures (PGTCS)Phase 3OngoingGlobalMajor Depressive Disorder (MDD)Phase 3OngoingGlobal
- XEN1120XEN1120 / Kv7 potassium channel opener / Small Molecule / PainPainPhase 1OngoingUnited States
- XEN1701XEN1701 / NaV1.7 sodium channel modulator / Small Molecule / PainPainPhase 1OngoingUnited States
- NBI-921355NBI-921355 / NaV1.2 / NaV1.6 sodium channel inhibitor / Small Molecule / NeurologyEpilepsyPhase 1OngoingGlobal
3assets
- SabirnetugACU193 / toxic soluble amyloid beta oligomers (AβOs) / humanized monoclonal antibody; intravenous formulation / NeurologyEarly Alzheimer's diseasePhase 2ongoing ALTITUDE-ADGlobal
- SabirnetugACU193 / toxic soluble amyloid beta oligomers (AβOs) / humanized monoclonal antibody; subcutaneous formulation / NeurologyEarly Alzheimer's diseasePhase 1clinical development
- Enhanced Brain Delivery (EBD™)TfR brain transporter + AβO mAb / blood-brain-barrier-penetrating antibody therapy / NeurologyEarly Alzheimer's diseasePreclinicalpreclinicalPre-clinical Alzheimer's diseasePreclinicalpreclinical
3assets
- Sodium oxybate extended-release oral suspensiononce-nightly extended-release oral suspension / Sleep disordersIdiopathic hypersomniaPhase 3Evaluating in REVITALYZ
- Olanzapine and samidorphanLYBALVI / oral small molecule combination / PsychiatrySchizophrenia and bipolar I disorder (pediatric)Phase 3Evaluating in ENLIGHTEN-Youth
- AlixorextonALKS 2680 / orexin 2 receptor / oral small molecule agonist / Sleep disordersNarcolepsy type 1Phase 3Brilliance Studies programNarcolepsy type 2Phase 3Brilliance Studies programIdiopathic hypersomniaPhase 2Vibrance-3
3assets
- APR-1051APR-1051 / WEE1 kinase / Oral small-molecule WEE1 inhibitor / OncologyCCNE1, CCNE2, FBXW7, PPP2R1A advanced solid tumorsPhase 1Monotherapy; potential safety/efficacy clinical data 2Q 2026; complete dose escalation 2Q 2027HPV+ oropharyngeal squamous cell carcinoma; cervical, vaginal or vulvar squamous cell carcinomaPhase 1MonotherapyKRAS G12/13 & TP53 colorectal cancerPhase 1Monotherapy
- ATRN-119ATRN-119 / Mosipasertib / ATR / Oral macrocyclic small-molecule ATR inhibitor / OncologyATRi synthetic lethal gene alterations in advanced solid tumors (ovarian, CRC, lung)Phase 1/2aMonotherapy; RP2D determinedHematological cancers (AML, MDS)Phase 1/2aMonotherapy; RP2D determined
- APR-1602APR-1602 / DYRK1 / Oral small-molecule DYRK1 inhibitor / OncologySolid tumors and hematological cancersIND-enablingReady to enter IND-enabling studies; milestone 4Q 2026
3assets
- AnaphylmAQST-109 / Anaphylm / epinephrine prodrug / dibutepinephrine sublingual film / Allergy/immunologyType 1 allergic reactions, including anaphylaxisNDA resubmission plannedclinical/regulatoryUS
- AQST-108AQST-108 / epinephrine prodrug / epinephrine topical gel / DermatologyMultiple potential indicationsPhase 1clinical
- LibervantLibervant / GABA-A receptor positive allosteric modulator / diazepam buccal film / NeurologyAcute repetitive seizures / cluster seizuresRegulatory/approvedpipeline-listedUS
3assets
- Topical Roflumilast CreamARQ-151 / ZORYVE / PDE4 / small molecule topical cream / DermatologyPlaque psoriasis 0.3% (2-5 yr)sNDA submittedPDUFA June 29, 2026USAtopic dermatitis 0.05% (3-24 mo)Phase 2planned sNDA submission Q2 2026US
- Topical Roflumilast FoamARQ-154 / ZORYVE / PDE4 / small molecule topical foam / DermatologyVitiligo 0.3%Phase 2acurrently enrolling; advancement decision Q4 2026Hidradenitis suppurativa 0.3%Phase 2acurrently enrolling; advancement decision Q1 2027
- ARQ-234ARQ-234 / CD200R / fusion protein biologic / DermatologyAtopic dermatitisPhase 1a/1benrolling
3assets
- AlloNKAB-101 / AlloNK® / CD20 combinations / Allogeneic off-the-shelf non-genetically modified cryopreserved NK cell therapy / Autoimmune disease; oncologyRefractory rheumatoid arthritisPhase 2aongoing; lead indication; Fast TrackUSSjögren’s diseasePhase 2aongoingUSIdiopathic inflammatory myopathiesPhase 2aongoingUS
- CAR-NKAB-205 / CD5 / Allogeneic anti-CD5 CAR-NK cell therapy expressing soluble IL-15 / OncologyHematologic malignanciesPreclinicalcollaborator-funded
- CAR-NKAB-201 / HER2 / Allogeneic anti-HER2 CAR-NK cell therapy expressing soluble IL-15 / OncologySolid tumorsPreclinicalcollaborator-funded; US orphan drug designationUS
3assets
- EfzofitimodNRP2 modulator / tRNA synthetase-derived biologic immunomodulator / Interstitial lung diseasePulmonary sarcoidosisPhase 3SSc-ILDPhase 2Other ILD (CTD-ILD; CHP)Phase 1
- ATYR0101ATYR0101 / LTBP1 modulator / FibrosisFibrosisPreclinical
- ATYR0750ATYR0750 / FGFR4 modulator / Liver disordersLiver disordersPreclinical
3assets
- ATR-12ATR-12 / LEKTI replacement / SPINK5 / Topical live biotherapeutic; engineered S. epidermidis expressing rhLEKTI-D6 / DermatologyNetherton syndromePhase 1bclinicalUS
- ATR-04ATR-04 / IL-36g reduction; S. aureus inhibition / Topical live biotherapeutic; auxotrophic engineered S. epidermidis strain SE484 / Dermatology / oncology supportive careEGFR inhibitor-associated rashPhase 1/2clinicalUS
- ATR-01ATR-01 / Filaggrin / FLG / Topical protein candidate; FLG5-6 with cell-penetrating peptide / DermatologyIchthyosis vulgarisPreclinicalpreclinical
3assets
- BGE - 102BGE-102 / NLRP3 / CNS-penetrant NLRP3 inhibitor / Metabolic diseasesCV riskPhase 1Diabetic macular edemaPhase 1
- APJ OralAPJ / APJ agonist / Metabolic diseasesObesityLead optimization
- APJ ParenteralAPJ / APJ agonist / Metabolic diseasesObesityLead optimization
3assets
- VTP-1000VTP-1000 / gluten antigens; mTOR inhibitor co-delivery / antigen-specific immunotherapy; SNAP Tolerance Platform / AutoimmunityCeliac diseasePreclinicalPhase 1 SAD data expected Q4 2025; MAD/challenge data in 2026Worldwide rights
- VTP-300VTP-300 / HBV antigens / HBV immunotherapeutic; ChAdOx/MVA viral vectors / Infectious diseasesChronic hepatitis BPhase 2Pursuing partnership opportunities for advancementWorldwide rights
- VTP-800/850VTP-800/850 / prostate cancer-associated antigens including PSA, PAP, STEAP1 and 5T4 / prostate cancer immunotherapeutic; ChAdOx/MVA viral vectors / CancerProstate cancerPhase 1Pursuing partnership opportunities for advancementWorldwide rights
3assets
- LOQTORZI (toripalimab-tpzi)LOQTORZI / PD-1 / Anti-PD-1 monoclonal antibody / Oncology1L Nasopharyngeal Carcinoma (combo with chemotherapy)ApprovedApprovedUnited States2L+ Nasopharyngeal Carcinoma (monotherapy)ApprovedApprovedUnited States
- TagmokitugCHS-114 / CCR8 / Anti-CCR8 monoclonal antibody / Oncology4L+ Colorectal Cancer (combo with toripalimab)Phase 22L HNSCC (combo with toripalimab)Phase 12L Gastric Cancer/GEJ/EAC (combo with toripalimab)Phase 1
- CasdozokitugIL-27 / IL-27 antagonist monoclonal antibody / Oncology1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)Phase 2
3assets
- CTx-1301CTx-1301 / PTR multi-core modified-release dexmethylphenidate tablet / CNSADHDNDA submittedSubmitted July 31, 2025US
- CTx-1302CTx-1302 / PTR multi-core modified-release dextroamphetamine tablet / CNSADHDPreclinical/formulationInitial formulation study plannedUS
- CTx-2103CTx-2103 / 5-HT1A partial agonist / PTR multi-core modified-release buspirone tablet / CNSAnxietyPre-INDClinical trials planned 4Q 2026US
3assets
- Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic; iodine-131 beta emitter / OncologyRelapsed/refractory Waldenström macroglobulinemiaPhase 2 pivotalcompletedRelapsed/refractory multiple myelomaPhase 2bongoingCNS lymphomaPhase 2bongoing
- CLR 121125CLR 125 / tumor cell nucleus via phospholipid ether platform / PLE radioconjugate; iodine-125 Auger emitter / OncologyRelapsed/refractory triple-negative breast cancerPhase 1bongoing
- CLR 121225CLR 225 / tumor cells via phospholipid ether platform / PLE radioconjugate; actinium-225 alpha emitter / OncologyPancreatic cancerPhase 1planned
3assets
- Budoprutug IVCD19 / monoclonal antibody / immune-mediated diseasesPrimary Membranous NephropathyPhase 2Immune ThrombocytopeniaPhase 1Systemic Lupus ErythematosusPhase 1
- Budoprutug SCCD19 / monoclonal antibody / immune-mediated diseasesAutoimmune DiseasePhase 1healthy volunteer trial
- CLYM116CLYM116 / APRIL / monoclonal antibody / immune-mediated diseasesIgA NephropathyPhase 1healthy volunteer trial
3assets
- cleminorextonORX750 / OX2R / oral orexin receptor 2 agonist / Sleep-wake disordersNarcolepsy Type 1 (NT1)Phase 2aactiveNarcolepsy Type 2 (NT2)Phase 2aactiveIdiopathic Hypersomnia (IH)Phase 2aactive
- ORX142ORX142 / OX2R / oral orexin receptor 2 agonist / Neurology/neurodegenerative disordersNeurological & neurodegenerative disordersPhase 1active
- ORX489ORX489 / OX2R / oral orexin receptor 2 agonist / NeuropsychiatryNeuropsychiatric disordersPreclinicalactive
3assets
- CTIM-76CTIM-76 / CLDN6 x CD3 / TCE bispecific antibody / Oncologyrecurrent ovarian cancer and other advanced solid tumorsPhase 1ongoingplatinum-resistant ovarian cancerPhase 1FDA Fast TrackUS
- CT-95CT-95 / MSLN x CD3 / TCE bispecific antibody / Oncologyadvanced solid tumorsPhase 1ongoing
- CT-202CT-202 / Nectin-4 x CD3 / TCE bispecific antibody / OncologyNectin-4-positive solid tumorsPhase 1planned; HREC approved and TGA CTN acknowledgedAustralia
3assets
- SoquelitinibCPI-818 / ITK / Oral small molecule ITK inhibitor / Immune diseases; oncologyRelapsed/refractory peripheral T-cell lymphoma (PTCL)Registration Phase 3EnrollingUnited StatesModerate-to-severe atopic dermatitisPhase 2Initiated/enrollingUnited StatesModerate-to-severe atopic dermatitisPhase 1b/2Enrolling; partner-ledChina
- CiforadenantCPI-444 / Adenosine A2A receptor / Oral small molecule checkpoint inhibitor / OncologyCancer indicationsClinical-stageGreater China
- MupadolimabCPI-006 / CD73 / Anti-CD73 monoclonal antibody / OncologyNon-small cell lung cancer (NSCLC)Phase 1/1bPartner-led evaluationChina
3assets
- varsetatug masetecanCX-2051 / Varseta-M / EpCAM / Probody ADC; Topo-1 payload / Oncology3L+ metastatic colorectal cancerPhase 1active2L/3L mCRC; Varseta-M + bevacizumabtrials anticipated 2H 20262L mCRC; Varseta-M + bevacizumab + chemotherapytrials anticipated 2H 2026
- CX-801CX-801 / IFN-alpha 2b / Probody cytokine / OncologyAdvanced/metastatic melanomaPhase 1active
- CX-908CX-908 / P-Cadherin x CD3 / Probody T-cell engager / OncologySolid tumorsPreclinicalactive
3assets
- HLP0035-HT2A and other serotonin receptors / Deuterated novel serotonergic agonist; oral / Mental healthAdjunctive treatment of Major Depressive Disorder (MDD)Phase 3Dosing underway; FDA Breakthrough Therapy Designation
- HLP004Serotonin receptors / Deuterated novel serotonergic agonist; intramuscular / Mental healthGeneralized Anxiety Disorder (GAD)Phase 2Enrollment complete
- HLP005CYB005 / Phenethylamines and tryptamines / CNS disordersCNS DisordersPreclinical
3assets
- TovorafenibDAY101 / OJEMDA / RAF / MAPK pathway / Oral small-molecule type II RAF inhibitor / OncologyBRAF-altered relapsed pLGGApprovedOJEMDA received FDA accelerated approval; FIREFLY-1 pivotal Phase 2 follow-up ongoing/disclosedU.S.Frontline RAF-altered pLGGPhase 3 / RegistrationalFIREFLY-2 pivotal Phase 3
- Emiltatug ledadotinEmi-Le / B7-H4 / Antibody-drug conjugate (ADC) / OncologyAdenoid cystic carcinoma (ACC), adult and pediatric solid tumorsPhase 1B7-H4-targeted ADC; Phase 1 data anticipated mid-2026 per company investor materials
- DAY301MTX-13 / CB-002 / PTK7 / Antibody-drug conjugate (ADC) / OncologyAdult and pediatric solid tumorsPhase 1Phase 1a data anticipated 2H 2026 per company investor materials
3assets
- EB06 Anti-CXCL10 Monoclonal antibodyEB06 / CXCL10 / Monoclonal antibody / Dermatological diseasesVitiligoPhase 2Health Canada CTA approved; IND in processCanadaUnited States
- EB01 (daniluromer)EB01 / sPLA2 / Topical sPLA2 inhibitor / Dermatological diseasesAllergic contact dermatitisPhase 2b completedTopline results available
- ParidiprubartEB05 / TLR4 / Monoclonal antibody / Respiratory diseasesAcute respiratory distress syndromePhase 3Phase 3 results reported; selected for U.S. government-funded Phase 2 platform studyUnited StatesCanada